Thu, Sep 18, 2014, 5:56 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

The Blackstone Group L.P. Message Board

rrtzrealmd 94 posts  |  Last Activity: 18 hours ago Member since: Aug 24, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I only just saw the PR announcing Hyperiscam had bought "Andromeda Biotech"! -- and ISRAELI scam biotech that runs in the same circles as DRIO and ORMP!...

    ...Andromeda lays claim to "DiaPep277" -- geez, even the name sounds like a scam! -- which "is a synthetic peptide of 24 amino acids derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide modulates the immune response that leads to autoimmune diabetes by diminishing or blocking the immunological destruction of beta cells."

    HAW!!! This is just too good!!! So in 1996 a company called "Peptor" is founded in Israel with 63 MILLION dollars in seed money (note to myself -- start a biotech company).

    Then about 20 YEARS ago, they develop this "immunomodulator" and calls it "diapep277." In 2001, they published a paper in Lancet about how it prevents beta cell loss in type 1 diabetics. Lo and behold, in 2002, Aventis pays Peptor 15 MILLION dollars to license the drug for further development and it was described as a "megadeal" by at least one analyst. ONE year later, Aventis RETURNS the drug to Peptor -- no explanation offered but pretty safe to presume they didn't think the drug was worth any further investment.

    I will continue this in another post since Yahoo has decided to limit length for some some reason.

  • Reply to

    About busted a gut laughing!!!

    by rrtzrealmd Jun 19, 2014 9:15 PM
    rrtzrealmd rrtzrealmd Jun 19, 2014 9:32 PM Flag

    In 2004, Peptor merges with "DeveloGen" -- a German biotech -- in order to unite "DeveloGen's efforts to develop treatments for obesity and diabetes with Peptor, whose products also target diabetes and other immune system conditions. The merged firm will develop a wide range of drugs to treat metabolic disease."

    Just THREE years later, in 2007, Develogen "sells" diapep277 to "Andromeda Biotech Ltd. ("Andromeda"), a newly formed wholly owned subsidiary of Clal Biotechnology." I say "sells" because apparently no money changed hands, Develogen just acquired royalties from "future sales" if the drug was ever commercialized.

    In 2009, Teva Pharmaceuticals licenses the drug from Andromeda. Ronny Gal, an ananlyst at Sanford Bernstein estimated " the market for the medicine to be about 50,000 patients a year at a price point of between $5,000 and $10,000 annually. The product is a “nice asset” for Teva, which will probably get 20 percent of sales as a royalty rate."

    In June 2010 Teva Pharmaceutical decided to exercise its option to invest in Andromeda Biotech receiving worldwide exclusive marketing rights to DiaPep277. It eventually would invest 170 MILLION dollars in Andromeda and diapep277 development and trials. The drug was even given orphan drug status by the FDA in 2012. It even completed a phase 3 trial in 2013: "Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (DIA-AID)"

    Then, in February of 2014, guess what! Andromeda BUYS BACK the rights for a "future payment" of 72 MILLION dollars. Let's see, spend 170 plus million then sell it for a "future" payment of 72 million? What does that tell you?

    Will continue in next post...

  • Reply to

    About busted a gut laughing!!!

    by rrtzrealmd Jun 19, 2014 9:15 PM
    rrtzrealmd rrtzrealmd Jun 19, 2014 10:19 PM Flag

    Explaining the repurchase of rights, "...Clal Biotech's board of directors audit committee says that Andromeda's buying back of the global rights to DiaPep277 from Teva was "important to accelerate the business development and commercialization and the drug that has taken place in recent months."

    Yeah, right! Like Teva decides to take a 100 million dollar loss because of all the "business development and commercilization" that had "taken place in recent months." How about, those American idiots are buying ANYTHING remotely biotech, so let's see if we can con them as well as we did Aventis and Teva!

    And now, lucky HPTX acquires Andomeda and all rights to diapep277 for the bargain basement price of -- drumroll please -- 20 MILLION dollars!!!

    Talk about a t__d rolling downhill! Why so cheap? Well, first, the autoimmune process can begin YEARS before actual clinical detection of diabetes. Now, for clinical symptoms to develop sufficiently to allow diagnosis, around 90% of the beta cells need to be destroyed. Treating with diascam277 might help preserve some of them, but it won't restore dead beta cells, so you're still insulin dependent, and there's no reason to believe that you won't still be subject to all the same problems every other IDDM patient faces. In other words, you might preserve beta cells, but so what? It's too late!

    And now you understand why Aventis and Teva and pretty much anyone with an IQ larger than a grapenut, walked away from it. Lucky HPTX, huh?

  • "Notice of exempt offering of securities"?????...hmmmmmmm...13 directors sold 8 MLLION dollars worth of stock?...nice little profit in there I bet!...and coming right after acquiring Andromedscam too!...what a coincidence!

  • Reply to

    Kinda funny actually...

    by rrtzrealmd Jun 12, 2014 9:28 PM
    rrtzrealmd rrtzrealmd Jun 20, 2014 11:13 AM Flag

    ...oh, look!...a "real" MD responding to bobblehead -- what's not to love!

  • Reply to

    I had to laugh...

    by rrtzrealmd Jun 13, 2014 10:46 PM
    rrtzrealmd rrtzrealmd Jun 20, 2014 11:17 AM Flag

    "...burned on EXEL..."???...no, I just enjoy showing morons -- like yourself -- how crooked biotechs are...go read my post on HPTX for yet ANOTHER great example...

  • I only just stumbled across it again. I vaguely remember laughing at it years ago when they said yhey were going to try to get approval to market wellbutrin as a weight loss drug and about fell over laughing...I remember wellbutrin became available as a generic just about the time these clowns went public SEVEN YEARS ago!...

    ...oh, look, and now they're mixing it with zonegran!...well, if mixing it with nalrexone won't work, why not!...if VVUS can get away ith it, why can't we!...HAW!...

    ...hmmmm...that reminds me, I wonder how those shareholder lawsuits against VVUS are working out -- the ones where the shareholders allege "breaches of the fiduciary duty...in connection with the launch of Qsymia...insider trading by some defendants for selling Company stock while purportedly being aware that the Qsymia launch would be less successful than predicted and corporate waste..."...corporate waste?...a biotech --- nawwwwww...HAW!...

    ...huh?...you say OREX already has its own lawsuits:

    "...assert claims for breach of fiduciary duty, waste and unjust enrichment based on, among other things, the alleged grant of stock options to certain officers in excess of the 162(m) Award Limit, repricing stock options allegedly in violation of the Company’s equity incentive plan, the board of directors’ conduct in responding to the May 2013 shareholder demand, and making allegedly false and misleading statements"

    ...awwwwww...unjust enrichment???...come on!...just because management gives itself fat salaries, benefits, bonuses, and perks while producing next to NOTHING for shareholders, no reason to get mean about it!...HAW!...and "false and misleading statements"????...hey, it's a biotech, already!...that comes with the territory, right?...HAW!!!...

  • Reply to

    Notch Signaling Article 2011

    by stocksifuca Jun 20, 2014 8:53 PM
    rrtzrealmd rrtzrealmd Jun 21, 2014 3:55 AM Flag

    ...yeah, I like that one line especially:

    "Although some academics say the entire class of therapeutics should be abandoned, at least one company—OncoMed Pharmaceuticals Inc.—thinks it's still business as usual because the gene knockout data that underpin the new study do not agree with the company's preclinical results."

    ...actually, probably MOST "academics" think the "entire class" should be abandoned...as far as the data "do not agree with the company's preclinical results" -- well, gee, of course not!...how could it?!...that would interfere with OMED's efforts to pull the wool over the eyes of naive investors while milking them for all they're worth!...

  • ....SCAM biotech!...I swear, these things breed like rabbits, don't they?...HAW!...

  • Reply to

    Notch Signaling Article 2011

    by stocksifuca Jun 20, 2014 8:53 PM
    rrtzrealmd rrtzrealmd Jun 23, 2014 9:40 AM Flag

    ...I hate to be redundant, but borrowing from my earlier post on the subject, was GSK "naive" when it invested in EXEL's XL228, XL820, and XL844 -- a deal which GSK TERMINATED three years later?...

    ...or was Genentech "naive" when it signed on with EXEL to develop notch inhibitors in 2005?...that's right, norch inhibitors!...by that time EXEL had ALREADY been working on the notch pathway for EIGHT YEARS!...did you know that one of the founders of EXEL -- Dr. Artavanis-Tsakonas -- is one of the big guns in notch research; you can google his name to find his notch lab at Harvard...

    ...after you do that, go over to EXEL's website and read about their current partners...won't see no Genentech...won't see no mention of notch anywhere...but they still got a BUNCH of other partners though...

    ...EXEL even has an APPROVED drug!...yessir, cometriq started on the market in the first quarter of 2013...last quarter EXEL reported revenues of a whopping 4.9 MILLION dollars from cometriq...and GSK gets a whopping THREE per cent of that!...nope, no naivety there!...

    ...were investors "naive" to pay up to $45 (yes, FORTY FIVE dollars) per share back in 2000...were they naive to hold the stock as it steadily sandk over the next fourteeen years?...and were they naive to buy stock in the secondary in January for $8 a share?...only to turn around and see the stock tank to THREE BUCKS only a couple of months later when EXEL announced results of an interim analysis of one of their trials?...

    ...and now any any not naive EXEL shareholder can point proudly to his whopping twenty five CENTS a share in equity while the stock trades at all of $3.50 per share!...ahhhhh, who would've dreamed of such enrichment...

  • rrtzrealmd by rrtzrealmd Jun 23, 2014 9:46 AM Flag

    Come on!...with 22 million shares?...market makers getting lazy or what?...

  • ...goodness, it seems like every other company I stumble over is an Israeli SCAM!...let's see, a million dollars in cash?...oh, yeah, that'll go a LONG way towards developing and marketing a product!...no partners???...no one even showing an interest in partnering???????...but!...but!!...it's such a "great" device -- massive potential, everyone'll want one!...now, buy my stock -- plueeeeeze!!!...HAW!!!...

  • rrtzrealmd by rrtzrealmd Jun 23, 2014 11:03 AM Flag

    ...three little Israeli scams!...four little, five little...well, you get my point...guess what -- I found another one this am!...I think I mentioned DRIO and its antique glucometer sometime previously, and this morning what did I find but a company called -- are you ready for this? -- "Integrity Applications"!!!...HAW!...is that rich or what?!

    ...anyway, IDAP has this marvelous non-invasive glucose monitoring system...unfortunately, they have hardly ANY money -- a million bucks or so -- so getting approvals and marketing are going to be kinda tough...and they also don't have any partners or, for that matter, anyone who appears even remotely interested in partnering...

    ...so, hey, maybe some of you suck...uhhhhhhhhhh..."speculative" investors might wanna bop over there help'em out!...why, heck, I worth they're worth every bit as much as Orascam!...HAW!!!...

  • Reply to

    One little, two little...

    by rrtzrealmd Jun 23, 2014 11:03 AM
    rrtzrealmd rrtzrealmd Jun 23, 2014 7:34 PM Flag

    ...oops!...my mistake -- IGAP, not IDAP...probably laughing to hard at the time!...

  • Reply to

    Drug efficacy and side effects datas

    by tanweikate Jun 22, 2014 8:21 AM
    rrtzrealmd rrtzrealmd Jun 23, 2014 8:00 PM Flag

    ...gee, are you referring to the PRELIMINARY results reported for all of SIX patients who were evaluated in a PHASE 1B trial in Australia, New Zealand, and that mecca of medical progress, SPAIN?...not to mention that it was not a blinded trial and how much you wanna bet there were some financial "incentives" for the parties involved?...

    ...regardless, you're still looking at a minimum of 4-5 YEARS before even the hope of a marketable product might rear its head...

  • Reply to

    Is there a corporate lawyer here?

    by antimatter0007 Jun 27, 2014 11:57 AM
    rrtzrealmd rrtzrealmd Jun 27, 2014 2:27 PM Flag

    ...get real!...they can't disclose names because there AIN'T ANY!...never have been, likely never will be!..."partners" are just part of the usual biotech hype train that pulls out of the station whenever the company is looking to pump its stock price -- as in, before a secondary, for example...all the potential partners already know what the company has and know what its REALLY worth -- result: no partners...

  • Reply to

    Is there a corporate lawyer here?

    by antimatter0007 Jun 27, 2014 11:57 AM
    rrtzrealmd rrtzrealmd Jun 27, 2014 2:31 PM Flag

    ...depth?...when you're talking about MNKD, who needs depth?...

  • ...The thrill is gone away, You know you've done me wrong, baby...And you'll be sorry someday...HAW, HAW, HAW!!!!

  • rrtzrealmd by rrtzrealmd Jul 1, 2014 12:08 PM Flag

    Well, afrezza has been running around the treadmill for what -- 7 - 10 YEARS? So it's safe to conclude ALL diabetics know about it, okay? Now, google "diabetes forum afrezza" and cruise through a few to get some idea how excited they are about the approval. Random quotes:

    "Lungs being one of the more vital body functions, I can't imagine agreeing to a new drug not knowing the long term effects."

    "I just don't understand how it could be precise enough for use with type 1."

    "...my mind just does not go there. Maybe it's because I'm asthmatic..."

    The most excitement I could find was the father of a kid who was happy to "welcome a new tool"! Too bad it'll be another THREE YEARS plus who knows how many millions (billions?) of dollars more before his kid even has a chance to try it!

    Indeed, I couldn't even find afrezza mentioned on several forums!

    Face it! Diabetics could care less about afrezza! The ONLY people "excited" about afrezza are stockbrokers and stock pumpers. Why? Because they want to selI STOCK and could less aboout the reality in store for afrezza.

  • Reply to

    Are diabetics "excited"?

    by rrtzrealmd Jul 1, 2014 12:08 PM
    rrtzrealmd rrtzrealmd Jul 1, 2014 9:34 PM Flag

    I'm going to quit talking to you...you got me to look at MNKD and when I saw what some of those idiots on seekingalpha were trying to claim, I felt compelled to offer an alternative view and there just isn't time to try and rebuke all the biotech scams currently trading...and that worries me because the last time biotechs got this "stupid" was back around 1999-2000 and the subsequen "correction" wasn't pretty -- to say the least...

    ...however, since my IMMR decided to bolt higher the past couple of days and I'm feeling generous, I'd say ARO has possibilities...minimal debt, goodwill, and intangibles...don't know what the company's excuse is for going from making two bucks a share 3 years ago to losing money this year...has an interested investor in Sycamore...so it's worth considering, but given what Sycamore did with Talbot's I'd be leery of risking much...but I haven't studied the 10Qs so maybe there's more than meets the eye...

BX
33.15+0.42(+1.28%)Sep 18 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.